spacer
home > pmps > winter 2019 > embracing spray drying strategies
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Embracing Spray Drying Strategies

Orally inhaled drug products have several therapeutic advantages over other dosage forms − most notably, a more direct delivery to the central nervous system. By their very nature, they avoid the first pass effect through the liver, for both regional as well as systemic delivery. This allows drug developers to formulate delivery strategies that reduce the dosage strength and limit the risk of adverse side effects. While pharmaceutical companies have long recognised the potential of inhalation products, many are starting to explore development techniques such as spray drying in more depth.

This article will outline the benefits of using respirable-engineered dry powder for inhalation products, as well as discussing how the new 505 (b) (2) application route for faster approval of new formulations that use existing APIs is a suitable pathway to getting these products to market quickly and efficiently.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
5
     

There are no comments in regards to this article.

spacer
Aditya R Das PhD, MBA is Director of Business Development at Recipharm and is focussed on inhalation drug product development and commercialisation for global clients. He is responsible for coordinating the interface between client needs and external services and capabilities to facilitate optimal product development and global registration. Aditya has over 25 yearsí experience working in combination biopharmaceutical product development, including pulmonary, transdermal, intravenous, implanted, and oral drug delivery therapeutic strategies and is an inventor on eight issued patents. He has a PhD in chemical engineering, an MBA from the University of California, US, an MS degree in chemical engineering from Carnegie Mellon University, US, and a BS degree in chemical engineering from the University of New Hampshire, US.
spacer
Aditya R Das PhD, MBA
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Nemera announces a better drug deposition with RetroNose to enhance therapeutic efficacy of nasal treatments

After announcing a partnership with the Research Center for Respiratory Diseases (CEPR) of Inserm/University of Tours in April 2017, Nemera is happy to publish enhanced drug deposition results compared to classic nasal sprays with RetroNose.
More info >>

White Papers

Running Better Trials Taking an Intelligent Monitoring Approach

Bioclinica

When it comes to implementing a risk-based monitoring program, it is not just about reducing monitoring visits and doing less Source Document Verification (SDV). Itís about bringing together your people, a solid process, and the right technology to run a better trial. Success with risk-based monitoring requires the ability to make sense of the thousands, if not millions, of data points captured by multiple disparate sources in a clinical trial. With the sheer volume of data generated on a daily basis comes complexity. How does one make sense of it all? Information overload burdens even the most experienced study teams who struggle to understand which data matters most and what it means.
More info >>

 
Industry Events

Multimodal 2019

18-20 June 2019, NEC, Birmingham, UK

Now in its twelfth year, Multimodal is the UK and Irelandís premier freight transport, logistics and supply chain management event.  Shippers and cargo owners attend to improve their businesses; by finding ways of moving their products more efficiently and by meeting new suppliers. 
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement